Lv31
241 积分 2023-03-27 加入
TCR-engineered T cell therapy in solid tumors: State of the art and perspectives
1小时前
待确认
Characterization of anti-CD3 antibodies in clinically available bispecific T cell engagers
1小时前
已完结
ImmTACs for targeted cancer therapy: Why, what, how, and which
1小时前
已完结
Mechanisms of T-cell Depletion in Tumors and Advances in Clinical Research
2小时前
已完结
Clinical implications of T cell exhaustion for cancer immunotherapy
2小时前
已完结
Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons
4小时前
已完结
ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells
1天前
已完结
Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells
1天前
已完结
Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma
1天前
已完结
Tebentafusp-tebn: A Novel Bispecific T-Cell Engager for Metastatic Uveal Melanoma
1天前
已完结
皖公网安备34019202002308
